Completion of a licence agreement granting Invitrogen access to one of OGT's Southern array patents, the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays
Oxford Gene Technology (OGT) and Invitrogen announce the completion of a licence agreement granting Invitrogen access to one of OGT's Southern array patents, the fundamental patents covering the manufacture and marketing of oligonucleotide microarrays.
The granted license will enable Invitrogen to offer DNA related microarray services, worldwide, from its US operations.
Sue Sutton, vice president licensing North America at OGT said: "Successful discussions with Invitrogen have concluded with the granting of this license thus enabling a world class company such as Invitrogen to expand their service base and adding to OGT's growing portfolio of North American licensees".
Amy Butler, vice president of Invitrogen's gene expression profiling business, commented that: "Invitrogen continually strives to provide complete and optimised solutions to its customers in terms of both its products and its services.
"This agreement will enable Invitrogen to provide a more complete offering to its customers who are interested in microarray services".
The licence will remain valid for the patents' lifetime.
Financial details were not disclosed.
